Do angiotensin converting enzyme inhibitors improve walking distance in patients with symptomatic lower limb arterial disease? A systematic review and meta-analysis of randomised controlled trials

International Journal of Surgery

Volumn 9, Issue 3, 2011, Pages 209-213

  Shahin, Yousef ^a   Mazari, Fayyaz ^a   Chetter, Ian ^a  

^a UNIVERSITY OF HULL   (United Kingdom)

Author keywords

Angiotensin converting enzyme inhibitors; Intermittent claudication; Peripheral arterial disease; Renin angiotensin system; Treadmill walking distance

Indexed keywords

CAPTOPRIL; CILAZAPRIL; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; PERINDOPRIL; RAMIPRIL;

ANKLE BRACHIAL INDEX; COUGHING; DRUG EFFECT; DRUG WITHDRAWAL; HUMAN; INTERMITTENT CLAUDICATION; META ANALYSIS; PERIPHERAL OCCLUSIVE ARTERY DISEASE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SYSTEMATIC REVIEW; WALKING;

AGED; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; ANKLE BRACHIAL INDEX; EXERCISE TEST; FEMALE; HUMANS; INTERMITTENT CLAUDICATION; LOWER EXTREMITY; MALE; MIDDLE AGED; PERIPHERAL ARTERIAL DISEASE; RANDOMIZED CONTROLLED TRIALS AS TOPIC; VASODILATOR AGENTS; WALKING;

EID: 79953308839     PISSN: 17439191     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ijsu.2010.12.006     Document Type: Review

References (20)

1. Newman A.B. Peripheral arterial disease: insights from population studies of older adults. J Am Geriatr Soc 2000, 48:1157-1162.
2. Ahimastos A.A., Lawler A., Reid C.M., Blombery P.A., Kingwell B.A. Brief communication: ramipril markedly improves walking ability in patients with peripheral arterial disease: a randomized trial. Ann Intern Med 2006, 144(9):660-664.
3. Clement D.L., Boccalon H., Dormandy J., Durand-Zaleski I., Fowkes G., Brown T. A clinical approach to the management of the patient with coronary (Co) and/or carotid (Ca) artery disease who presents with leg ischaemia (Lis). Int Angiol 2000, 19(2):97-125.
4. Gibbons G.H. Mechanisms of vascular remodeling in hypertension: role of autocrine-paracrine vasoactive factors. Curr Opin Nephrol Hypertens 1995, 4(2):189-196.
5. Bhatt D.L., Steg P.G., Ohman E.M., Hirsch A.T., Ikeda Y., Mas J.L., et al. International prevalence, recognition, and treatment of cardiovascular risk factors in outpatients with atherothrombosis. JAMA 2006, 295(2):180-189.
6. Antman E.M., Anbe D.T., Armstrong P.W., Bates E.R., Green L.A., Hand M., et al. ACC/AHA guidelines for the management of patients with ST-elevation myocardial infarction: a report of the American College of Cardiology/American heart Association Task Force on Practice Guidelines (Committee to Revise the 1999 Guidelines for the management of patients with Acute Myocardial Infarction). Circulation 2004, 110(9):e82-292.
7. Coppola G., Romano G., Corrado E., Grisanti R.M., Novo S. Peripheral artery disease: potential role of ACE-inhibitor therapy. Vasc Health Risk Manag 2008, 4(6):1179-1187.
8. Kawano H., Do Y.S., Kawano Y., Starnes V., Barr M., Law R.E., et al. Angiotensin II has multiple profibrotic effects in human cardiac fibroblasts. Circulation 2000, 101(10):1130-1137.
9. Ahimastos A.A., Natoli A.K., Lawler A., Blombery P.A., Kingwell B.A. Ramipril reduces large-artery stiffness in peripheral arterial disease and promotes elastogenic remodeling in cell culture. Hypertension 2005, 45(6):1194-1199.
10. Effects of an angiotensin converting enzyme inhibitor, ramipril, on cardiovascular events in high risk patients. N Eng J Med 2000, 342:145-153. The Heart Outcomes Prevention Evaluation (HOPE) Study Investigators.
11. Ostergren J., Sleight P., Dagenais G., Danisa K., Bosch J., Qilong Y., et al. Impact of ramipril in patients with evidence of clinical or subclinical peripheral arterial disease. Eur Heart J 2004, 25(1):17-24.
12. Bjorholt I., Anderson F.L., Kahan T., Ostergren J. The cost-effectiveness of ramirpil in the treatment of patients at high risk of cardiovascular events: a Swedish sub-study to the HOPE study. J Int Med 2002, 251:508-517.
13. Lamy A., Yusuf S., Pogue J., Gafni A. Heart outcomes prevention Evaluation Invetsigators. Cost implications of the use of ramipril in high-risk patients based on the heart outcomes prevention Evaluation (HOPE) study. Circulation 2003, 107:960-965.
14. Smith M.G., Neville A.M., Middleton J.C. Clinical and economic benefits of ramipril: an Australian analysis of the HOPE study. Int Med J 2003, 33:414-419.
15. Jadad A.R., Moore R.A., Carroll D., Jenkinson C., Reynolds D.J., Gavaghan D.J., et al. Assessing the quality of reports of randomised clinical trials: is blinding necessary. Control Clin Trials 1996, 17:1-12.
16. Roberts D.H., Tsao Y., Mcloughlin G.A., Breckenridge A. Placebo-controlled comparison of captopril, atenolol, labetolol and pindolol in hypertension complicated by intermittent claudication. Lancet 1987, 2(8560):650-653.
17. Spence J.D., Arnold J.M.O., Munoz C.E., Viswanatha A., Huff M., Derose G., et al. Angiotensin-converting enzyme inhibition with cilazapril does not improve blood flow, walking time, or plasma lipids in patients with intermittent claudication. J Vasc Med Biol 1993, 4(1):23-28.
18. Overlack A., Adamczak M., Bachmann W., Bonner G., Bretzel R.G., Derichs R., et al. ACE-inhibition with perindopril in essential hypertensive patients with concomitant diseases. The Perindopril Theraputic Safety Collaborative Research Group. Am J Med 1994, 97(2):126-134.
19. Cochrane handbook for systematic reviews of interventions Version 5.0.1 2008, updated September 2009, The Cochrane Collaboration, Available from. http://www.cochrane-handbook.org, J.P. Higgins, S. Green (Eds.).
20. Review Manager (RevMan) [Computer program]. Version 5.0 2008, The Nordic Cochrane Centre, The Cochrane Collaboration, Copenhagen.